View Filing Data

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2014	Feb. 13, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	MIMEDX GROUP, INC.
Entity Central Index Key	0001376339
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 657
Entity Common Stock, Shares Outstanding		106,594,879
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 46,582	$ 44,078
Short term investments	5,750	0
Accounts receivable, net	26,672	16,093
Inventory, net	5,133	3,881
Prepaid expenses and other current assets	1,540	1,337
Total current assets	85,677	65,389
Investments	3,250	0
Property and equipment, net of accumulated depreciation	5,447	4,086
Goodwill	4,040	4,040
Intangible assets, net of accumulated amortization	10,845	11,179
Total assets	109,259	84,694
Current liabilities:
Accounts payable	3,661	2,491
Accrued compensation	11,523	5,588
Accrued expenses	2,504	1,406
Other current liabilities	716	123
Total current liabilities	18,404	9,608
Other liabilities	1,526	1,518
Total liabilities	19,930	11,126
Commitments and contingencies (Note 17)
Stockholders' equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock; $0.001 par value; 130,000,000 shares authorized; 108,776,247 issued and 107,789,611 outstanding at December 31, 2014 and 104,425,614 issued and 104,375,614 outstanding at December 31, 2013	108	104
Additional paid-in capital	162,433	147,284
Treasury stock at cost: 986,636 shares at December 31, 2014 and 50,000 shares at December 31, 2013	(5,637)	(25)
Accumulated deficit	(67,575)	(73,795)
Total stockholders' equity	89,329	73,568
Total liabilities and stockholders' equity	$ 109,259	$ 84,694

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2014	Dec. 31, 2013
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	130,000,000	130,000,000
Common stock, shares issued (in shares)	108,776,247	104,425,614
Common stock, shares outstanding (in shares)	107,789,611	104,375,614
Treasury stock, shares (in shares)	986,636	50,000

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Net sales	$ 118,223	$ 59,181	$ 27,053
Cost of sales	12,665	9,328	5,188
Gross margin	105,558	49,853	21,865
Operating expenses:
Research and development expenses	7,050	4,843	2,885
Selling, general and administrative expenses	90,480	46,227	19,591
Impairment of intangible assets	0	368	1,798
Fair value adjustment of earn-out liability	0	0	1,567
Amortization of intangible assets	928	1,054	1,380
Operating income (loss)	7,100	(2,639)	(5,356)
Other income (expense), net
Amortization of debt discount	0	(1,328)	(1,714)
Interest expense, net	(48)	(45)	(593)
Income (loss) before income tax provision	7,052	(4,012)	(7,663)
Income tax provision	(832)	(100)	0
Net income (loss)	$ 6,220	$ (4,112)	$ (7,663)
Net income (loss) per common share - basic (in dollars per share)	$ 0.06	$ (0.04)	$ (0.09)
Net income (loss) per common share - diluted (in dollars per share)	$ 0.05	$ (0.04)	$ (0.09)
Weighted average shares outstanding - basic (in shares)	105,793,008	96,285,504	81,646,295
Weighted average shares outstanding - diluted (in shares)	113,295,504	96,285,504	81,646,295

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Deficit
Balance at Dec. 31, 2011	$ 11,898	$ 74	$ 73,869	$ (25)	$ (62,020)
Balance (in shares) at Dec. 31, 2011		74,306,895		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	2,539		2,539
Exercise of stock options	1,053	$ 1	1,052
Exercise of stock options (in shares)		843,863
Exercise of warrants	6,001	$ 8	5,993
Exercise of warrants (in shares)		7,959,767
Common stock issued for 5% convertible note	0
Repurchase warrants	(1)		(1)
Cashless exercise of warrants (in shares)		216,085
Common stock issued for accrued director fees	184		184
Common stock issued for accrued director fees (in shares)		167,086
Common stock issued for earn-out liability	3,186	$ 3	3,183
Common stock issued for earn-out liability (in shares)		2,632,576
Discount on beneficial conversion feature	514		514
Common stock issued for acquisition note	$ 893	$ 1	892
Common stock issued for acquisition note (in shares)	893,267	893,267
Conversion of line of credit with related party	$ 1,403	$ 1	1,402
Conversion of line of credit with related party (in shares)		1,403,630
Shares issued for services performed	0
Net income (loss)	(7,663)				(7,663)
Balance at Dec. 31, 2012	20,007	$ 88	89,627	$ (25)	(69,683)
Balance (in shares) at Dec. 31, 2012		88,423,169		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	6,010		6,010
Exercise of stock options	1,981	$ 2	1,979
Exercise of stock options (in shares)		1,958,674
Exercise of warrants	2,108	$ 2	2,106
Exercise of warrants (in shares)		1,844,352
Common stock issued for 5% convertible note	5,272	$ 5	5,267
Common stock issued for 5% convertible note (n shares)		5,272,004
Common stock issued for accrued director fees	0
Common stock issued for earn-out liability	$ 5,792	$ 1	5,791
Common stock issued for earn-out liability (in shares)	2,632,576	1,174,915
Common stock issued for acquisition note (in shares)	893,267
Conversion of line of credit with related party	$ 0
Conversion of line of credit with related party (in shares)	1,403,630
Public offering of common stock, net of expenses	$ 36,510	$ 6	36,504
Public offering of common stock, net of expenses (in shares)		5,750,000
Issuance of restricted stock (in shares)		2,500
Shares issued for services performed	0
Net income (loss)	(4,112)				(4,112)
Balance at Dec. 31, 2013	73,568	$ 104	147,284	$ (25)	(73,795)
Balance (in shares) at Dec. 31, 2013		104,425,614		50,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	11,453		11,453
Exercise of stock options	$ 2,470	$ 2	2,468
Exercise of stock options (in shares)	1,653,690	1,653,690
Exercise of warrants	$ 1,113	$ 1	1,112
Exercise of warrants (in shares)		1,242,416
Common stock issued for 5% convertible note	$ 0
Common stock issued for 5% convertible note (n shares)	5,272,004
Common stock issued for accrued director fees	$ 0
Common stock issued for earn-out liability	$ 0
Common stock issued for earn-out liability (in shares)	1,174,915
Common stock issued for acquisition note (in shares)	893,267
Conversion of line of credit with related party	$ 0
Issuance of restricted stock		$ 1	(1)
Issuance of restricted stock (in shares)		1,438,569
Shares issued for services performed	$ 117		$ 117
Shares issued for services performed (in shares)	15,958	15,958
Stock repurchase	$ (5,612)			$ (5,612)
Stock repurchase (in shares)	940,000			936,636
Net income (loss)	$ 6,220				6,220
Balance at Dec. 31, 2014	$ 89,329	$ 108		$ (5,637)	$ (67,575)
Balance (in shares) at Dec. 31, 2014		108,776,247	162,433,000	986,636

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)	Dec. 31, 2013	Dec. 31, 2011
5% Convertible Senior Secured Promissory Note
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible note	5.00%	5.00%

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	$ 6,220	$ (4,112)	$ (7,663)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation	1,197	637	465
Loss on fixed asset disposal	0	37	0
Amortization of intangible assets	928	1,054	1,380
Impairment of intangible assets	0	368	1,798
Amortization of debt discount and deferred financing costs	0	1,328	1,714
Share-based compensation	11,453	6,010	2,539
Change in fair value of earn-out liability	0	0	1,567
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(10,579)	(8,439)	(5,762)
Inventory	(1,252)	(858)	(2,310)
Prepaid expenses and other current assets	(203)	(707)	(466)
Other assets	0	70	97
Accounts payable	1,287	1,209	(81)
Accrued compensation	5,935	2,836	2,355
Accrued expenses	1,098	353	606
Accrued interest	0	(42)	388
Other liabilities	718	(28)	41
Net cash flows from operating activities	16,802	(284)	(3,332)
Cash flows from investing activities:
Purchases of equipment	(2,558)	(2,337)	(637)
Purchases of fixed maturity securities	(9,000)	0	0
Patent application costs	(594)	(689)	0
Net cash flows from investing activities	(12,152)	(3,026)	(637)
Cash flows from financing activities:
Proceeds from exercise of stock options	2,470	1,981	1,053
Proceeds from exercise of warrants	1,113	2,108	6,001
Proceeds from public offering, net of expenses	0	36,602	0
Stock repurchase	(5,612)	0	0
Repayment of convertible debt related to acquisition	0	0	(427)
Principal payments of equipment leases	(117)	(57)	(16)
Repurchase of warrants	0	0	(1)
Net cash flows from financing activities	(2,146)	40,634	6,610
Net change in cash	2,504	37,324	2,641
Cash and cash equivalents, beginning of period	44,078	6,754	4,113
Cash and cash equivalents, end of period	$ 46,582	$ 44,078	$ 6,754

Nature of Business	12 Months Ended
Nature of Business	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Nature of Business MiMedx Group, Inc. (“MiMedx,” "the Company,” “we,” or “us”) operates in one business segment, Regenerative Biomaterials, which includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. The Company's biomaterial platform technologies include tissue technologies, AmnioFix® and EpiFix®, and device technology CollaFix^™,which the Company has yet to commercialize. The Company is focused primarily on the United States but will pursue other individual markets based upon the specific opportunity. The adoption of the technologies may vary depending on each country’s regulations, but the opportunities to help individuals in the different disease states remain similar and large.

Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation

The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., SpineMedica, LLC, and MiMedx Tissue Services, LLC, formerly known as Surgical Biologics, LLC. All significant inter-company balances and transactions have been eliminated.

Segment Reporting

ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment. Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment. Thus, discrete financial information is not available for more than one operating segment.

Market Concentrations and Credit Risk

The Company places its cash and cash equivalents on deposit with financial institutions in the United States. In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts. As of December 31, 2014, the Company had cash and cash equivalents of approximately $44,600,000 in excess of the insured amounts.

The Company’s principal market concentration of risk is related to its limited distribution channels. The Company's revenues include the distribution efforts of several independent companies as well as the Company's internal sales force. Significant revenues are derived from its relationship with one of its distributors, AvKare, Inc. which sells our products to the Federal government. For the years ended December 31, 2014, 2013 and 2012, AvKare revenue was 34%, 56%, and 40% of total revenue, respectively. Related receivables for the same time periods were 33%, 55%, and 53%, of total accounts receivable, respectively.

Cash and Cash Equivalents

Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

Investments

Investments include FDIC insured certificates of deposit held at various banks and are classified as either Short term investments or Investments depending on their maturity date and are valued at cost, which approximates market value.

Inventories

Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method. Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes upon work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates. Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.

Goodwill and Purchased Intangible Assets

Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.

Impairment of Intangible Assets with Finite Lives

The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.

Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.

During the fourth quarter of 2013, the Company chose to discontinue the HydroFix^® product line. This action resulted in an impairment charge of approximately $368,000 related to the Licenses for SaluMedica LLC, Spine Repair and Polyvinyl Alcohol Cryogel. This item is included in our Statement of Operations for the year ended December 31, 2013. An impairment charge of approximately $1,800,000 had previously been booked in 2012.

Property and Equipment

Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years. Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term. See Notes 7 and 17 for further information regarding capital leases, operating leases and rent expense.

Patent Costs

The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company. The Company capitalized approximately $594,000 of patent costs during 2014 and approximately $689,000 of patent costs during 2013. There were no patent costs capitalized in 2012.

Impairment of Long-lived Assets

The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated. If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized. During the fourth quarter of 2013, the Company chose to discontinue the HydroFix® product line. This action resulted in a disposal loss of approximately $30,000. This item is included in the Consolidated Statements of Operations for the year ended December 31, 2013, as Selling, General and Administrative expenses.

Grant Income

The Company received a Regional Economic Business Assistance ("REBA") grant in the amount of $250,000 from the State of Georgia to help the Company defray certain expenses and capital expenditures related to the Company's expansion of manufacturing activities in the State. In order to retain the grant monies the Company was required to add a certain number of full time positions and spend a certain amount on capital and operations expenditures by December 31, 2014. As of December 31, 2013, the Company had satisfied the grant requirements. Accordingly, the Company recorded the $250,000 as a reduction of Selling, General and Administrative expenses in the accompanying 2013 Consolidated Statements of Operations.

Debt Instruments with Detachable Warrants and Beneficial Conversion Features

According to ASC470-20 "Debt With Conversion and Other Options", proceeds from the sale of convertible debt instruments with stock purchase warrants (detachable call options) shall be allocated to the two elements based upon the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion of the proceeds so allocated to the warrants shall be accounted for as paid-in capital. The remainder of the proceeds shall be allocated to the debt instrument portion of the transaction. Also, the embedded beneficial conversion feature present in the convertible instrument shall be recognized separately at issuance by allocating a portion of the proceeds equal to the intrinsic value of that feature to additional paid-in capital.

Revenue Recognition

The Company sells its products primarily through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. In cases where the Company utilizes distributors or ships products directly to the end user, it recognizes revenue according to the shipping terms of the agreement provided all revenue recognition criteria have been met. A portion of the Company’s revenue is generated from inventory maintained at hospitals or with field representatives. For these products, revenue is recognized at the time the product has been used or implanted. The Company records estimated sales returns, discounts and allowances as a reduction of net sales in the same period revenue is recognized.

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.

Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that included the enactment date. Valuation allowances are recorded for deferred tax assets when the recoverability of such assets is not deemed more likely than not.

Uncertain Tax Positions

Tax positions are evaluated in a two-step process. The Company first determines whether it is more likely than not that a tax position will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to recognize in the financial statements. The tax position is measured as the largest amount of benefit that is more than 50% likely of being realized upon ultimate settlement. The Company classifies gross interest and penalties and unrecognized tax benefits that are not expected to result in payment or receipt of cash within one year as non-current liabilities in the Consolidated Balance Sheets. Based on the process stated above, no adjustments were recognized for uncertain tax positions at December 31, 2014.

Share-based Compensation

The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).

Fair Value of Financial Instruments

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates its carrying value based upon current rates available to the Company.

Fair Value Measurements

The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments. The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2014, the Company has not chosen to make any such elections. Fair value financial instruments are recorded in accordance with the fair value measurement framework.

The Company also measures certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations. The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.

The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows:


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist it in determining fair value, as appropriate.

Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.

Recently Issued Accounting Pronouncements

The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2016 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements. All other ASUs issued effective and not yet effective for the year ended December 31, 2014, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.

Liquidity and Capital Resources	12 Months Ended
Liquidity and Capital Resources	Dec. 31, 2014
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	Liquidity and Capital Resources Net Working Capital As of December 31, 2014, the Company had approximately $46,582,000 of cash and cash equivalents. The Company reported total current assets of approximately $85,677,000 and current liabilities of approximately $18,404,000 and had net working capital of approximately $67,273,000. Overall Liquidity and Capital Resources The Company's largest cash requirement for the twelve months ended December 31, 2014 was cash for general working capital needs. In addition, the Company's other cash requirements included capital expenditures, and repurchases of the Company's common stock. The Company funded its cash requirements through its existing cash reserves, and its operating activities which generated approximately $16,800,000 during the period. The Company believes that its anticipated cash from operating and financing activities and existing cash and cash equivalents as well as its investments in FDIC insured certificates of deposit will enable the Company to meet its operational liquidity needs and fund its planned investing activities for the next year.

Cash Equivalents and Short Term Investments	12 Months Ended
Cash Equivalents and Short Term Investments	Dec. 31, 2014
Cash and Cash Equivalents [Abstract]
Cash Equivalent and Short Term Investments	Cash Equivalents and Short Term Investments Included in Cash and cash equivalents as of December 31, 2014 are approximately $1,250,000 of FDIC insured certificates of deposit held with various financial institutions. Short term investments consist of approximately $5,750,000 of FDIC insured certificates of deposits held with various financial institutions. The cost of these instruments approximates their fair market value at December 31, 2014. As of December 31, 2013, Cash and cash equivalents consisted of cash balances only. There were no Short term investments as of December 31, 2013.

Inventories

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventories

Inventories consisted of the following items as of December 31, 2014 and 2013 (in thousands):



	December 31,
	2014			2013
Raw materials	$	255		$	202
Work in process	3,419			2,952
Finished goods	1,986			1,049
Inventory, gross	5,660			4,203
Reserve for obsolescence	(527		)	(322		)
Inventory, net	$	5,133		$	3,881

Investments (Notes)	12 Months Ended
Investments (Notes)	Dec. 31, 2014
Investments, All Other Investments [Abstract]
Investments	Investments Investments consist of FDIC insured certificates of deposit with various U.S. financial institutions that have maturities ranging from February 2016 to May 2016. The balance as of December 31, 2014 was approximately $3,250,000 and the cost approximates fair market value. There were no investments as of December 31, 2013.

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consist of the following as of December 31, 2014 and 2013 (in thousands):



	December 31,
	2014			2013
Leasehold improvements	$	2,559		$	2,320
Lab and clean room equipment	3,040			2,025
Furniture and equipment	2,398			1,241
Construction in Progress	949			802
Property and equipment, gross	8,946			6,388
Less accumulated depreciation	(3,499		)	(2,302		)
Property and equipment, net	$	5,447		$	4,086

Included in property and equipment is approximately $250,000 of capital leases. The corresponding liability is included in other liabilities in the accompanying condensed consolidated balance sheet. Also included is approximately $1,000,000 in leasehold improvements paid for by the landlord of our new facility with a corresponding liability included in long term liabilities, which is amortized over the term of the lease.

Depreciation expense for the years ended December 31, 2014, 2013, and 2012 was approximately $1,197,000, $637,000, and $465,000, respectively.

Intangible Assets and Royalty Agreement

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Royalty Agreement

Intangible assets are summarized as follows (in thousands):



		December 31,
		2014			2013
	Weighted Average Amortization Lives	Cost			Cost
Licenses (a) (b)	10 years	$	1,009		$	1,009
Patents & Know How (b)	17 years	7,891			7,799
Customer & Supplier Relationships (b)	14 years	3,761			3,761
Tradenames & Trademarks (b)	indefinite	1,008			1,008
In Process Research & Development (b)	n/a	25			25
Patents in Process (c)	n/a	1,082			580
Total		14,776			14,182
Less Accumulated amortization		(3,931		)	(3,003		)
Net		$	10,845		$	11,179

(a)

On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2014, this license had a remaining net book value of approximately $209,000.

(b)

On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2014 approximately $92,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.


(c)	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Amortization expense for the years ended December 31, 2014, 2013, and 2012, was approximately $928,000, $1,054,000, and $1,380,000, respectively.

Expected future amortization of intangible assets as of December 31, 2014, is as follows (in thousands):



	Estimated
	Amortization
Year ending December 31,	Expense
2015	$	929
2016	929
2017	840
2018	830
2019	830
Thereafter	5,479
	$	9,837

Long-Term Debt	12 Months Ended
Long-Term Debt	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Senior Secured Promissory Notes From December 27 to December 31, 2011, the Company sold 5% Convertible Senior Secured Promissory Notes (the “Notes”) to individual accredited investors for aggregate proceeds of $5,000,000. The aggregate proceeds included $500,000 of Notes sold to the Company’s Chairman of the Board and CEO. In total, the principal of the Notes were convertible into up to 5,000,000 shares of common stock of the Company (“Common Stock”) plus accrued but unpaid interest at $1.00 per share at any time upon the election of the holder of the note. In conjunction with the sale of the Notes, the Company incurred a placement fee of $32,800 and issued 42,400 common stock warrants to the placement agents at an exercise price of $1.09 per share. The warrants expire in December 2016. The fair value of the warrants was determined to be approximately $15,000 using the Black-Scholes-Merton valuation technique. The total direct costs of approximately $47,800 were recorded as deferred financing costs and were amortized over the term of the Notes using the effective interest method. Further, the placement agent warrants are classified in stockholders’ equity because they achieved all of the requisite conditions for equity classification in accordance with GAAP. During the months of January and February 2013, all holders of the Notes converted their interest in this obligation to shares of MiMedx common stock. The total amount of debt plus accrued interest that was exchanged was approximately $5,272,000. In conjunction with this exchange, approximately 5,272,000 shares of the Company’s common stock were issued in full satisfaction of this obligation. Included in this total are 532,260 shares representing the Chief Executive Officer’s conversion of his Note. This also resulted in the acceleration of amortization of debt discount and total interest expense of approximately $1,328,000 during the year ended December 31, 2013 and approximately $1,714,000 during the year ended December 31, 2012. Line of Credit On May 1, 2014, the Company's $3,000,000 revolving line of credit with Bank of America, N.A. expired and the Company chose not to renew. There were no borrowings outstanding at any time under this facility.

Net Income (loss) Per Share

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Net Income (loss) Per Share

Basic net income (loss) per common share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and convertible debt using the treasury stock method.

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):



	Year Ended December 31,
	2014		2013			2012
Net income (loss)	$	6,220	$	(4,112	)	$	(7,663	)
Denominator for basic earnings per share - weighted average shares	105,793,008		96,285,504			81,646,295
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	7,502,496		—			—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	113,295,504		96,285,504			81,646,295
Income (loss) per common share - basic	0.06		(0.04		)	(0.09		)
Income (loss) per common share - diluted	$	0.05	$	(0.04	)	$	(0.09	)

(a)Securities outstanding that are included in the computation above, utilizing the treasury stock method for the year end December 31, 2014 are as follows:



Outstanding Stock Options	7,036,088
Outstanding Warrants	226,926
Restricted Stock Awards	239,482
	7,502,496

Securities outstanding for years ended December 31, 2013 and 2012 were excluded from the computation of diluted earnings per share because they would have been anti-dilutive.

Common Stock Placements	12 Months Ended
Common Stock Placements	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Common Stock Placements	Common Stock Placements Public Offering of Common Stock In December of 2013, the Company completed a public offering ("The Offering”) of 5,750,000 shares of its common stock at $6.80 per share. Proceeds from The Offering net of underwriting expenses of the Offering were $36,704,000. In addition, the Company incurred approximately $194,000 in various legal fees for services related to The Offering. Proceeds from The Offering are used for general corporate purposes, including, but not limited to, research, development and further commercialization of our products, obtaining regulatory approvals, funding of our clinical trials, capital expenditures, working capital and future acquisitions of complementary businesses, technology or products, although we currently have no agreements or commitments with respect to any such investment or acquisition.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Equity

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity

Stock Incentive Plans

The Company has three share-based compensation plans: the MiMedx Group, Inc. Assumed 2006 Stock Incentive Plan (the “2006 Plan”), the MiMedx Inc. 2007 Assumed Stock Plan (the “Assumed 2007 Plan”) and the MiMedx Group Inc. Amended and Restated Assumed 2005 Stock Plan (the “Assumed 2005 Plan”) which provide for the granting of qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors. The awards are subject to a vesting schedule as set forth in each individual agreement. The Company intends to use only the 2006 Plan to make future grants. The number of assumed options under the Assumed 2005 Plan and Assumed 2007 Plan outstanding at December 31, 2014, totaled 195,000. On July 28, 2014, the Company's shareholders approved 4,000,000 additional shares to be made available under the 2006 Plan, bringing the maximum number of shares of common stock that can be issued under the 2006 Plan to 26,500,000 at December 31, 2014.

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2014	15,375,960		$	2.46
Granted	3,132,969		$	7.20
Exercised	(1,653,690	)	$	1.49
Unvested options forfeited	(296,680	)	$	4.09
Vested options expired	(84,332	)	$	0.81
Outstanding at December 31, 2014	16,474,227		$	3.43	7.3	$	133,360,210
Vested at December 31, 2014	9,280,650		$	1.97	6.5	$	88,716,569
Vested or expected to vest at December 31, 2014 (a)	16,198,892		$	3.38	7.3	$	131,953,654


(a)	Includes forfeiture adjusted unvested shares.

The intrinsic value of the options exercised during the years ended December 31, 2014, 2013 and 2012 were approximately $10,566,000, $8,864,000, and $719,000, respectively.

The intrinsic value of options vested during the years ended December 31, 2014, 2013 and 2012 were approximately $6,615,000, $3,351,000, and $1,851,000, respectively.

Following is a summary of stock options outstanding and exercisable at December 31, 2014:



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	632,500	4.4	$	0.72	632,500	$	0.72
$0.87 - $1.35	5,861,595	6.6	1.20		4,989,245	1.19
$1.40 - $2.29	1,460,201	5.0	1.64		1,338,532	1.65
$2.33 - $3.75	1,737,339	7.7	2.77		1,079,147	2.78
$3.95 - $5.99	3,365,030	8.4	5.15		977,415	5.10
$6.02- $9.13	3,287,562	8.8	7.06		263,811	6.47
$9.22 - $10.99	130,000	9.9	10.42		—	—
	16,474,227	7.3	$	3.43	9,280,650	$	1.97

A summary of the status of the Company’s unvested stock options as of December 31, 2014 is presented below:



Unvested Stock Options	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested at January 1, 2014	8,568,228		$	1.94
Granted	3,132,969		$	4.18
Cancelled	(296,680	)	$	4.09
Vested	(4,210,940	)	$	1.58
Unvested at December 31, 2014	7,193,577		$	3.08

Total unrecognized compensation expense at December 31, 2014, was approximately $15,084,000 and will be charged to expense ratably through December 2017.

The fair value of the options granted was estimated on the date of grant using the Black-Scholes-Merton option-pricing model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. Expected volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the options. The term of employee options granted is derived using the “simplified method” which computes expected term as the midpoint between the weighted average time to vesting and the contractual maturity. The simplified method was used due to the Company’s lack of sufficient historical data to provide a reasonable basis upon which to estimate the expected term due to the limited period of time its equity shares have been publicly traded. The term for non-employee options is generally based upon the contractual term of the option. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term or contractual term as described.

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Year ended December 31,
	2014	2013	2012
Expected volatility	58.14 - 64.5%	61.41 - 64.77%	45.7 - 64.3%
Expected life (in years)	6	6	6
Expected dividend yield	—	—	—
Risk-free interest rate	1.64 - 1.96%	0.85 - 1.88%	0.62 - 1.77%

The weighted-average grant date fair value for options granted during the years ended December 31, 2014 , 2013 and 2012 were approximately $4.18 , $3.08 and $1.07, respectively.

Restricted Stock Awards

Following is summary information for restricted stock awards for the years ended 2014 and 2013. Shares vest over a one to three year period. As of December 31, 2014, there was approximately $6,637,000 of total unrecognized stock-based compensation related to time-based, non-vested restricted stock. That expense is expected to be recognized on a straight-line basis over a weighted-average period of 2.2 years.

Additionally, during the twelve months ended December 31, 2014, 8,411 shares of common stock valued at approximately $70,000 were issued under the 2006 Plan to a consultant in return for services performed.



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at January 1, 2014	576,550		$	5.53
Granted	862,739		$	7.88
Vested	(209,671	)	$	5.71
Forfeited	(720	)	$	7.24
Unvested at December 31, 2014	1,228,898		$	5.53

For the years ended December 31, 2014, 2013, and 2012 the Company recognized stock-based compensation as follows (in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of sales	$	322	$	279	$	98
Research and development	660		417		289
Selling, general and administrative	10,471		5,314		2,152
	$	11,453	$	6,010	$	2,539

Warrants

From time to time the Company has granted common stock warrants in connection with equity share purchases by investors as an additional incentive for providing long - term equity capital to the Company and as additional compensation to consultants and advisors. The warrants were granted at negotiated prices in connection with the equity share purchases and at the market price of the common stock in other instances. The warrants were issued for terms of five years.

Common Stock warrants activity and resulting balances for the years ended December 31, 2014 and 2013 are as follows:



	Number of Warrants		Weighted- Average Exercise Price per Warrant
Warrants outstanding at January 1, 2014	1,284,816		$	0.90
Warrants exercised	(1,242,416	)	$	0.90
Warrants outstanding at December 31, 2014	42,400		$	1.09

Warrants may be exercised in whole or in part by:


•	notice given by the holder accompanied by payment of an amount equal to the warrant exercise price multiplied by the number of warrant shares being purchased; or

•

if permitted by the applicable warrant election by the holder to exchange the warrant (or portion thereof) for that number of shares equal to the product of (a) the number of shares issuable upon exercise of the warrant (or portion) and (b) a fraction, (x) the numerator of which is the market price of the shares at the time of exercise minus the warrant exercise price per share at the time of exercise and (y) the denominator of which is the market price per share at the time of exercise.

These warrants are not mandatorily redeemable, and do not obligate the Company to repurchase its equity shares by transferring assets or issuing a variable number of shares.

The warrants require that the Company deliver shares as part of a physical settlement or, if permitted by the applicable warrant a net-share settlement, at the option of the holder, and do not provide for a net-cash settlement.

All of the Company's warrants are classified as equity as of December 31, 2014 and expire in December of 2016.

Treasury Stock

On May 12, 2014, the Company announced that its Board of Directors had authorized the repurchase of up to $10,000,000 of its common stock from time to time, through December 31, 2014. On December 12, 2014, the Board extended this program until December 31, 2015. On January 5, 2015, the Board increased the authorization under the program to $20,000,000. The timing and amount of repurchases, if any, will depend upon the Company's stock price, economic and market conditions, regulatory requirements, and other corporate considerations. The Company may initiate, suspend or discontinue purchases under the stock repurchase program at any time.

For the year ended December 31, 2014, the Company purchased approximately 940,000 shares of its common stock for an aggregate purchase price of approximately $5,600,000. As of December 31, 2014, the Company had approximately $4,400,000 remaining under the repurchase program.

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):



	December 31,
	2014			2013
Deferred tax assets and liabilities:
Accruals and prepaids	$	3,563		$	1,404
Intangible assets	619			1,163
Property and equipment	(770		)	(507		)
R&D and other tax credits	2,086			1,369
Stock compensation	4,163			2,151
Charitable contributions	1			1
Federal and state basis difference	114			—
Net operating loss	6,382			14,663
Net deferred tax assets	$	16,158		$	20,244

Valuation allowance	(16,158		)	(20,244		)
	$	—		$	—

The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:



	December 31,
	2014		2013
Federal statutory rate	34.00	%	34.00	%
State taxes, net of federal benefit	9.58	%	(2.48	)%
Non deductible compensation	5.59	%	—	%
Meals & entertainment	5.55	%	—	%
Stock based compensation - ISO	21.73	%	—	%
Other	(5.92	)%	12.73	%
Valuation allowance	(58.73	)%	(46.73	)%
	11.80	%	(2.48	)%

Income taxes are based on estimates of the annual effective tax rate and evaluations of possible future events and transactions and may be subject to subsequent refinement or revision.

Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefit that, based on available evidence, is not expected to be realized. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely. At December 31, 2014, the Company had a valuation allowance of approximately $16,158,000 recorded against the benefit of certain deferred tax assets. In assessing the recoverability of our deferred tax assets, we analyzed all evidence, both positive and negative. The Company considered, among other things, our deferred tax liabilities, our historical earnings and losses, projections of future income, and tax-planning strategies available to us in the relevant jurisdiction.

As a result of anticipated profitability for the year and positive trends in the foreseeable future, the Company may release all or a portion of this valuation allowance by the end of 2015. However, the exact timing and amount of the valuation allowance released are subject to change based on the level of profitability that the Company is able to actually achieve for the year and its visibility into future period results. The potential release of this valuation allowance during 2015 would have a material impact on the Company's recorded tax expense in the period of reversal. The Company will release this valuation allowance when management determines that it is more likely than not that its deferred tax asset will be realized.

At December 31, 2014, the Company has income tax net operating loss ("NOL") carry forwards for federal and state purposes of approximately $15,323,000 and approximately $21,196,000, respectively. The Company has recorded a deferred tax asset for both federal and state income taxes of approximately $5,210,000 and approximately $1,172,000, respectively. If not utilized, the federal and state tax loss carry forwards will expire between 2026 and 2031.

As a result of certain realization requirements of ASC 718, Compensation - Stock Compensation, the table of deferred tax assets and liabilities shown above does not include certain deferred tax assets as of December 31, 2014, and December 31, 2013, that arose directly from (or the use of which was postponed by) tax deductions related to equity compensation that are greater than the compensation recognized for financial reporting. Equity will be increased by approximately $5,676,000 if and when such deferred tax assets are ultimately realized. The Company uses ASC 740 ordering when determining when excess tax benefits have been realized.

The Company's net operating losses and credits are subject to annual limitations due to ownership change limitations provided by Internal Revenue Code Section 382. The Company has performed an analysis and determined that the limitation exceeds the utilization of NOLs in the current year and does not anticipate much limitation going forward.

In July 2006, the FASB issued Interpretation 48 (codified primarily in ASC 740), which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with Statement 109 (codified primarily in ASC 740). Interpretation 48 provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. Income tax positions must meet a more-likely-than-not recognition threshold at the effective date to be recognized upon the adoption of Interpretation 48 and in subsequent periods. As a result of the implementation, the Company has analyzed its tax positions and determined that no reserve is necessary at this time.

The Company is subject to taxation in the US and various state jurisdictions. As of December 31, 2014, the Company’s tax years for 2011, 2012 and 2013 are subject to examination by the tax authorities. As of December 31, 2014, the Company is generally no longer subject to US federal, state, or local examinations by tax authorities for years before 2011.

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

12 Months Ended

Dec. 31, 2014

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows (in thousands):



	Twelve Months Ended December 31,
	2014		2013		2012
Cash paid for interest	$	48	$	36	$	13
Income taxes paid	384		61		—
Purchases of equipment financed through capital leases	—		355		85
Stock issuance of 167,086 shares in lieu of Directors' fees	—		—		184
Deferred financing costs	—		27		20
Beneficial conversion related to Line of Credit with related party	—		—		514
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares for 2013 and 2,632,576 shares for 2012	—		5,792		3,186
Stock issuance in exchange for convertible debt of 5,272,004 shares	—		5,272		—
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	—		—		1,403
Stock issuance of 15,958 shares in exchange for services performed	117		—		—
Stock issuance of 216,085 shares for exercise of cashless warrants	—		—		216
Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes related to acquisition of Surgical Biologics	—		—		893
Tenant improvement incentive	—		997		—
Legal fees paid for public offering	—		102		—
Legal fees related to public offering included in accounts payable	—		30		—
Legal fees related to public offering included in accrued expenses	—		62		—

Related Party Transactions

12 Months Ended

Dec. 31, 2014

Related Party Transactions

The Company has related party expense as described in the following table (in thousands):



	December 31,
	2014		2013		2012
Office space lease (a)	$	—	$	70	$	48
Aircraft use (b)	10		11		—
Furniture (c)	41		—		—
Line of credit (d)	—		—		104
Convertible senior secured promissory notes (e)	—		—		50
	$	51	$	81	$	202


(a)	payments related to the lease of office space from an entity owned by the Chairman of the Board and CEO


(b)	payments related to aircraft use from an entity owned by the Chairman of the Board and CEO


(c)	payment to Chairman of the Board and CEO for office furniture purchased for Company headquarters


(d)	interest related to a revolving secured line of credit extended by the Chairman of the Board and CEO dated March 31, 2011


(e)	interest related to the convertible senior secured promissory notes issued to the Chairman of the Board and CEO during the fourth quarter of 2011

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

401k Plan	12 Months Ended
401k Plan	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
401k Plan	401k Plan The Company has a 401(k) plan (the “Plan”) covering employees who have attained 21 years of age and have completed three months of service. Under the Plan, participants may defer up to 100% of their eligible wages to a maximum of $17,500 per year (annual limit for 2014). Employees age 50 or over in 2014 may make additional pre-tax contributions up to $5,500 above and beyond normal plan and legal limits. Annually, the Company may elect to match employee contributions up to 6% of the employee’s compensation. Additionally, the Company may elect to make a discretionary contribution to the Plan. The Company did not provide matching contributions for the years ended December 31, 2014, 2013 and 2012.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Contractual Arrangements

In addition to the capital leases noted under Property and Equipment above, the Company has entered into operating lease agreements for facility space and equipment. These leases expire over the next six years and generally contain renewal options. The Company anticipates that most of these leases will be renewed or replaced upon expiration. The Company also has commitments for meeting space and to various charitable organizations.

The estimated annual payments are as follows (in thousands):



Year ended December 31,
2015	$	2,094
2016	1,924
2017	1,535
2018	1,434
2019	120
	$	7,107

Rent expense for the years ended December 31, 2014, 2013 and 2012, was approximately $1,130,000, $1,000,000 and $485,000, respectively and is allocated among cost of sales, research and development, and selling, general and administrative expenses.

Letters of Credit

As a condition of the leases for the Company's facilities we are obligated under standby letters of credit in the amount of approximately $500,000. These obligations are reduced at various times over the lives of the leases.

FDA Untitled Letter and Related Litigation

Initially, MiMedx processed its tissue allografts in only one form, which was a sheet form. In 2011, MiMedx introduced a micronized form of its sheet allografts.

The FDA has specific regulations governing human cells, tissues and cellular and tissue-based products, or HCT/Ps. An HCT/P is a product containing or consisting of human cells or tissue intended for transplantation into a human patient. If an HCT/P meets the criteria for regulation solely under Section 361 of the Public Health Service Act (so-called “361 HCT/Ps”), no FDA review for safety and effectiveness under a drug, device, or biological product marketing application is required.

MiMedx believes that all of its tissue products qualify as 361 HCT/Ps. On August 28, 2013, however, the FDA issued an Untitled Letter alleging that the Company’s micronized allografts do not meet the criteria for regulation solely under Section 361 of the Public Health Service Act and that, as a result, MiMedx would need a biologics license to lawfully market the micronized products.

In November 2013, the FDA clarified the basis for its position regarding the micronized products. Specifically, the FDA explained its belief that “[c]ryo-milling cut, dehydrated amniotic/chorionic membrane results in a micron-sized powder and the loss of the tensile strength and elasticity that are essential characteristics of the original amniotic/chorionic tissue relating to its utility to function as a ‘physical membrane’ (i.e. covering, barrier).” The Company responded to the FDA that while it does not agree with the FDA’s position, it understands the FDA’s interest in further regulating this emerging technology. Accordingly, the Company proposed to the FDA that it would pursue the Investigational New Drug (“IND”) and Biologics License Application (“BLA”) process for certain micronized products, and, in parallel, also proposed to enter into negotiations with the FDA on a plan to transition the micronized products to licensed biological products and continue to market the micronized products under specific conditions.

On July 22, 2014, the Company filed its first IND application with the FDA. The application was allowed, paving the way for a Phase IIB clinical trial of its micronized product for a specified indication of use in anticipation of a BLA, which the Company expects to submit at a future date. The clinical trial is expected to enroll approximately 150 patients in 10 - 20 clinical sites in the U.S. The Company anticipates initiating the trial in the first half of 2015.

The Company also requested a transition agreement to allow it to continue to market its current micronized products for certain specified uses while pursuing one or more BLAs. The Agency continues to assert that the current form of the Company’s micronized products are more than minimally manipulated and therefore are not eligible for marketing solely under Section 361 of the Public Health Service Act. The Company has conducted tests and has engaged independent laboratories to conduct tests that confirm that tensile strength and modulus of elasticity are not diminished by the process used by the Company to create its micronized products.

On December 22, 2014, the FDA issued for comment “Draft Guidance for Industry: Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products.” Essentially the draft guidance takes the same position with respect to micronized amniotic tissue that it took in the Untitled Letter to MiMedx 16 months earlier.

The period for submitting comments on the Draft Guidance expired on February 23, 2015. The Company has submitted comments to the Draft Guidance asserting that the Draft Guidance represents agency action that goes far beyond FDA’s statutory authority, is inconsistent with existing HCT/ P regulations and FDA’s prior positions as well as internally inconsistent and is scientifically unsound. Additionally, the Company asked the FDA to allow MiMedx to continue to market its micronized products until the guidance or regulations as the case may be have been fully vetted through a process of notice and comment rule making. Preliminarily, FDA has indicated that it intends to issue for comment Draft Guidance on homologous use later this year and that industry and other interested parties will have an opportunity to comment on both guidance documents as a whole at that time.

If the FDA does allow the Company to continue to market a micronized form of its sheet allografts either prior to or after finalization of the Draft Guidance, it may impose conditions, such as labeling restrictions and compliance with Current Good Manufacturing Practices (“cGMP”). It is also possible that the FDA will not allow the Company to market any form of a micronized product without a biologics license even prior to finalization of the Draft Guidance and could even require the Company to recall its micronized products. Revenues from micronized products comprised approximately 14% of the Company's revenues in 2014.

Following the publication of the Untitled Letter from the FDA regarding the Company’s micronized products in September 2013, the trading price of the Company’s stock dropped sharply and several purported class action lawsuits were filed against the Company and certain of its executive officers asserting violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to various statements and alleged omissions related to the Company’s belief that its products were 361 HCT/Ps, including its micronized products. These cases have now all been removed to, and consolidated in, the United States District Court for the Northern District of Georgia. By order dated December 9, 2013, the Court approved the appointment of a lead plaintiff and a lead counsel. A Consolidated Amended Class Action Complaint, containing substantially the same causes of action and claims for relief as the initial complaints, was filed on January 27, 2014. The case is currently in the discovery phase. The Company currently believes that the outcome of this litigation will not have a material adverse impact on the Company's financial position or results of operations.

Other Shareholder Litigation

On February 19, 2015, one of the law firms that filed one of the class action lawsuits referenced above filed a separate purported class action lawsuit against the Company and certain of its executive officers in the United States District Court for the Southern District of New York. The suit alleges violations of the Securities Act of 1933 and the Securities Exchange Act of 1934 with respect to various statements and alleged omissions related to the Company’s receipt of a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG. The subpoena is discussed in more detail below. The Company has not yet been served in the lawsuit. If and when it is served, the Company intends to vigorously defend the suit. Currently, the Company believes that the outcome of this litigation will not have a material adverse impact on the Company's financial position or results of operations.

Patent Litigation

On April 22, 2014, the Company filed a patent infringement lawsuit against Liventa Bioscience, Inc. ("Liventa"), Medline Industries, Inc. ("Medline") and Musculoskeletal Transplant Foundation, Inc. ("MTF") for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of certain of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients, and in some cases, prospective investors. The suit was filed in the United States District Court for the Northern District of Georgia. In the suit, MiMedx asserts that Liventa (formerly known as AFCell Medical, Inc.), Medline and MTF infringed and continue to infringe certain of the Company’s patents relating to the MiMedx dehydrated human amnion/chorion membrane ("dHACM") allografts. MTF is the processor and Liventa and Medline are the distributors of the allegedly infringing products. On May 30, 2014, the defendants filed answers to the Complaint, denying the allegations in the Complaint. They also raised affirmative defenses of non-infringement, invalidity, laches and estoppel. MTF and Medline also filed counterclaims seeking declaratory judgments of non-infringement and invalidity. On May 16, 2014, the Company also filed a patent infringement lawsuit against Transplant Technology, Inc. d/b/a Bone Bank Allografts (“Bone Bank”) and Texas Human Biologics, Ltd. (“Biologics”) for permanent injunctive relief and unspecified damages. The lawsuit was filed in the United States District Court for the Western District of Texas. This lawsuit similarly asserts that Bone Bank and Biologics infringed certain of the Company’s patents through the manufacturing and sale of tissue graft products. The defendants have denied the allegations in the Complaint. They also have raised affirmative defenses of non-infringement and invalidity and filed counterclaims seeking declaratory judgments of non-infringement and invalidity. The lawsuits currently are in the discovery and claim construction phases. In addition to defending the pending district court litigations, to avoid the high burden of proof required to prove invalidity of our patent claims in the district court litigation, the defendants have filed several requests for inter-partes review by the Patent Trial and Appeal Board seeking to invalidate some of our patent claims.

On March 2, 2015, the Company filed a patent infringement lawsuit against Nutech Medical, Inc. (“Nutech”) and DCI Donor Services, Inc. (“DCI”) for permanent injunctive relief and unspecified damages. This lawsuit has been filed in the United States District Court for the Northern District of Alabama. The lawsuit alleges that Nutech and DCI have infringed and continue to infringe MiMedx’s patents through the manufacture, use , sale, and/or offering of their tissue graft product. The lawsuit also asserts that Nutech knowingly and willfully made false and misleading representations about its products to customers and/or prospective customers.

OIG Subpoena

In the fourth quarter of 2014, the Company received a subpoena from the Office of Inspector General, U.S. Department of Health and Human Services, or OIG, in connection with a civil investigation into matters primarily related to the Company's sales and marketing activities. This Company is cooperating fully with the government in its investigation, and has produced numerous responsive documents.

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

Quarterly Financial Data (Unaudited) (in thousands except per share data)



		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
NET SALES	2014	$	19,559		$	25,573		$	33,518		$	39,573
	2013	11,556			13,515			16,116			17,994
	2012	3,706			4,884			7,954			10,509

GROSS MARGIN	2014	$	16,582		$	22,833		$	30,170		$	35,973
	2013	9,651			11,316			14,002			14,883
	2012	2,747			3,769			6,529			8,820

NET INCOME	2014	$	(922	)	$	(390	)	$	3,700		$	3,832
	2013	(1,620		)	(757		)	(307		)	(1,427		)
	2012	(1,094		)	(744		)	(4,219		)	(1,605		)

NET INCOME (LOSS) PER COMMON SHARE - BASIC	2014	$	(0.01	)	$	—		$	0.03		$	0.04
	2013	(0.02		)	(0.01		)	—			(0.01		)
	2012	(0.01		)	(0.01		)	(0.05		)	(0.01		)

NET INCOME (LOSS) PER COMMON SHARE - DILUTED	2014	$	(0.01	)	$	—		$	0.03		$	0.03
	2013	(0.02		)	(0.01		)	—			(0.01		)
	2012	(0.01		)	(0.01		)	(0.05		)	(0.01		)

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 6, 2015, the Company's Board of Directors increased the Company’s authorization for its share repurchase plan from $10,000,000 to $20,000,000. From January 1, 2015 to the date of this report the Company has purchased approximately $12,300,000 of common stock under this plan bringing the total spending under the plan to $17,800,000. On February 24, 2015, the Company entered into a lease agreement under which the Company will lease approximately 26,000 square feet of office space in Marietta, Georgia. The initial term of the lease agreement is sixty three (63) months commencing on June 1, 2015. Base rental payments over the term of the lease total approximately $1,600,000. On March 5, 2015, Anthem Insurance Companies, Inc. ("Anthem") approved EpiFix for coverage to treat Diabetic Foot Ulcers (DFUs) and Venus Leg Ulcers (VLUs). Anthem has 34,000,000+ members across 14 states. With the addition of Anthem, MiMedx has now secured coverage for EpiFix for approximately 149 million covered lives which represents about 60% of the total covered lives available with the commercial carriers.

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2014

Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts

Schedule II Valuation and Qualifying Accounts



MIMEDX GROUP, INC. AND SUBSIDIARIES SCHEDULE II VALUATION AND QUALIFYING ACCOUNTS
Years ended December 31, 2014, 2013 and 2012 (in thousands)

	Balance at Beginning of Year		Additions charged to Expense or Revenue		Deductions and write-offs			Balance at End of Year

For the Year ended December 31, 2014
Allowance for doubtful accounts	$	407	$	1,357	$	(14	)	$	1,750
Allowance for product returns	215		2,215		(1,589		)	841
Allowance for obsolescence	322		405		(200		)	527

For the Year ended December 31, 2013
Allowance for doubtful accounts	$	49	$	391	$	(33	)	$	407
Allowance for product returns	89		917		(791		)	215
Allowance for obsolescence	159		213		(50		)	322

For the Year ended December 31, 2012
Allowance for doubtful accounts	$	19	$	57	$	(27	)	$	49
Allowance for product returns	88		394		(393		)	89
Allowance for obsolescence	53		106		—			159

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

Segment Reporting

Market Concentrations and Credit Risk

Cash and Cash Equivalents

Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.

Accounts Receivable

Accounts receivable represent amounts due from customers for which revenue has been recognized. Generally, the Company does not require collateral or any other security to support its receivables.

Investments

Inventories

Goodwill and Purchased Intangible Assets

Impairment of Intangible Assets with Finite Lives

Property and Equipment

Patent Costs

Impairment of Long-lived Assets

Grant Income

Debt Instruments with Detachable Warrants and Beneficial Conversion Features

Revenue Recognition

Research and Development Costs

Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.

Income Taxes

Uncertain Tax Positions

Share-based Compensation

Fair Value of Financial Instruments

Fair Value Measurements


•	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;


•	Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.


•	Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.

Recently Issued Accounting Pronouncements

Inventories (Tables)

12 Months Ended

Dec. 31, 2014

Inventory Disclosure [Abstract]

Inventory

Inventories consisted of the following items as of December 31, 2014 and 2013 (in thousands):



	December 31,
	2014			2013
Raw materials	$	255		$	202
Work in process	3,419			2,952
Finished goods	1,986			1,049
Inventory, gross	5,660			4,203
Reserve for obsolescence	(527		)	(322		)
Inventory, net	$	5,133		$	3,881

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and equipment

Property and equipment consist of the following as of December 31, 2014 and 2013 (in thousands):



	December 31,
	2014			2013
Leasehold improvements	$	2,559		$	2,320
Lab and clean room equipment	3,040			2,025
Furniture and equipment	2,398			1,241
Construction in Progress	949			802
Property and equipment, gross	8,946			6,388
Less accumulated depreciation	(3,499		)	(2,302		)
Property and equipment, net	$	5,447		$	4,086

Intangible Assets and Royalty Agreement (Tables)

12 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible assets activity summary

Intangible assets are summarized as follows (in thousands):



		December 31,
		2014			2013
	Weighted Average Amortization Lives	Cost			Cost
Licenses (a) (b)	10 years	$	1,009		$	1,009
Patents & Know How (b)	17 years	7,891			7,799
Customer & Supplier Relationships (b)	14 years	3,761			3,761
Tradenames & Trademarks (b)	indefinite	1,008			1,008
In Process Research & Development (b)	n/a	25			25
Patents in Process (c)	n/a	1,082			580
Total		14,776			14,182
Less Accumulated amortization		(3,931		)	(3,003		)
Net		$	10,845		$	11,179

(a)

(b)


(c)	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.

Estimated future amortization expense for intangible assets

Expected future amortization of intangible assets as of December 31, 2014, is as follows (in thousands):



	Estimated
	Amortization
Year ending December 31,	Expense
2015	$	929
2016	929
2017	840
2018	830
2019	830
Thereafter	5,479
	$	9,837

Net Income (loss) Per Share (Tables)

12 Months Ended

Dec. 31, 2014

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net income (loss) per share (in thousands except per share data):



	Year Ended December 31,
	2014		2013			2012
Net income (loss)	$	6,220	$	(4,112	)	$	(7,663	)
Denominator for basic earnings per share - weighted average shares	105,793,008		96,285,504			81,646,295
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (a)	7,502,496		—			—
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities	113,295,504		96,285,504			81,646,295
Income (loss) per common share - basic	0.06		(0.04		)	(0.09		)
Income (loss) per common share - diluted	$	0.05	$	(0.04	)	$	(0.09	)

(a)Securities outstanding that are included in the computation above, utilizing the treasury stock method for the year end December 31, 2014 are as follows:

Summary of Antidilutive Securities

Securities outstanding that are included in the computation above, utilizing the treasury stock method for the year end December 31, 2014 are as follows:



Outstanding Stock Options	7,036,088
Outstanding Warrants	226,926
Restricted Stock Awards	239,482
	7,502,496

Equity (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock options activity

Activity with respect to the stock options is summarized as follows:



	Number of Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at January 1, 2014	15,375,960		$	2.46
Granted	3,132,969		$	7.20
Exercised	(1,653,690	)	$	1.49
Unvested options forfeited	(296,680	)	$	4.09
Vested options expired	(84,332	)	$	0.81
Outstanding at December 31, 2014	16,474,227		$	3.43	7.3	$	133,360,210
Vested at December 31, 2014	9,280,650		$	1.97	6.5	$	88,716,569
Vested or expected to vest at December 31, 2014 (a)	16,198,892		$	3.38	7.3	$	131,953,654


(a)	Includes forfeiture adjusted unvested shares.

Summary of stock options outstanding and exercisable

Following is a summary of stock options outstanding and exercisable at December 31, 2014:



	Options Outstanding				Options Exercisable
Range of Exercise Prices	Number outstanding	Weighted- Average Remaining Contractual Term (in years)	Weighted- Average Exercise Price		Number Exercisable	Weighted- Average Exercise Price
$0.50 - $0.76	632,500	4.4	$	0.72	632,500	$	0.72
$0.87 - $1.35	5,861,595	6.6	1.20		4,989,245	1.19
$1.40 - $2.29	1,460,201	5.0	1.64		1,338,532	1.65
$2.33 - $3.75	1,737,339	7.7	2.77		1,079,147	2.78
$3.95 - $5.99	3,365,030	8.4	5.15		977,415	5.10
$6.02- $9.13	3,287,562	8.8	7.06		263,811	6.47
$9.22 - $10.99	130,000	9.9	10.42		—	—
	16,474,227	7.3	$	3.43	9,280,650	$	1.97

Unvested Stock Options Roll Forward

A summary of the status of the Company’s unvested stock options as of December 31, 2014 is presented below:



Unvested Stock Options	Number of Shares		Weighted- Average Grant Date Fair Value
Unvested at January 1, 2014	8,568,228		$	1.94
Granted	3,132,969		$	4.18
Cancelled	(296,680	)	$	4.09
Vested	(4,210,940	)	$	1.58
Unvested at December 31, 2014	7,193,577		$	3.08

Fair value of options valuation assumptions

The assumptions used in calculating the fair value of options using the Black-Scholes-Merton option-pricing model are set forth in the following table:



	Year ended December 31,
	2014	2013	2012
Expected volatility	58.14 - 64.5%	61.41 - 64.77%	45.7 - 64.3%
Expected life (in years)	6	6	6
Expected dividend yield	—	—	—
Risk-free interest rate	1.64 - 1.96%	0.85 - 1.88%	0.62 - 1.77%

Restricted Stock Awards Roll Forward



	Number of Shares		Weighted-Average Grant Date Fair Value
Unvested at January 1, 2014	576,550		$	5.53
Granted	862,739		$	7.88
Vested	(209,671	)	$	5.71
Forfeited	(720	)	$	7.24
Unvested at December 31, 2014	1,228,898		$	5.53

Allocation of Share-based Compensation

For the years ended December 31, 2014, 2013, and 2012 the Company recognized stock-based compensation as follows (in thousands):



	Year Ended December 31,
	2014		2013		2012
Cost of sales	$	322	$	279	$	98
Research and development	660		417		289
Selling, general and administrative	10,471		5,314		2,152
	$	11,453	$	6,010	$	2,539

Summary of warrants outstanding

Common Stock warrants activity and resulting balances for the years ended December 31, 2014 and 2013 are as follows:



	Number of Warrants		Weighted- Average Exercise Price per Warrant
Warrants outstanding at January 1, 2014	1,284,816		$	0.90
Warrants exercised	(1,242,416	)	$	0.90
Warrants outstanding at December 31, 2014	42,400		$	1.09

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Deferred tax assets and liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands):



	December 31,
	2014			2013
Deferred tax assets and liabilities:
Accruals and prepaids	$	3,563		$	1,404
Intangible assets	619			1,163
Property and equipment	(770		)	(507		)
R&D and other tax credits	2,086			1,369
Stock compensation	4,163			2,151
Charitable contributions	1			1
Federal and state basis difference	114			—
Net operating loss	6,382			14,663
Net deferred tax assets	$	16,158		$	20,244

Valuation allowance	(16,158		)	(20,244		)
	$	—		$	—

Reconciliation of the Federal statutory income tax

The reconciliation of the Federal statutory income tax rate of 34% to the effective rate is as follows:



	December 31,
	2014		2013
Federal statutory rate	34.00	%	34.00	%
State taxes, net of federal benefit	9.58	%	(2.48	)%
Non deductible compensation	5.59	%	—	%
Meals & entertainment	5.55	%	—	%
Stock based compensation - ISO	21.73	%	—	%
Other	(5.92	)%	12.73	%
Valuation allowance	(58.73	)%	(46.73	)%
	11.80	%	(2.48	)%

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Tables)

12 Months Ended

Dec. 31, 2014

Supplemental Cash Flow Elements [Abstract]

Supplemental Disclosure of Cash Flow and Non-cash Investing and Financing Activities

Selected cash payments, receipts, and noncash activities are as follows (in thousands):



	Twelve Months Ended December 31,
	2014		2013		2012
Cash paid for interest	$	48	$	36	$	13
Income taxes paid	384		61		—
Purchases of equipment financed through capital leases	—		355		85
Stock issuance of 167,086 shares in lieu of Directors' fees	—		—		184
Deferred financing costs	—		27		20
Beneficial conversion related to Line of Credit with related party	—		—		514
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares for 2013 and 2,632,576 shares for 2012	—		5,792		3,186
Stock issuance in exchange for convertible debt of 5,272,004 shares	—		5,272		—
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	—		—		1,403
Stock issuance of 15,958 shares in exchange for services performed	117		—		—
Stock issuance of 216,085 shares for exercise of cashless warrants	—		—		216
Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes related to acquisition of Surgical Biologics	—		—		893
Tenant improvement incentive	—		997		—
Legal fees paid for public offering	—		102		—
Legal fees related to public offering included in accounts payable	—		30		—
Legal fees related to public offering included in accrued expenses	—		62		—

Related Party Transactions (Tables)

12 Months Ended

Dec. 31, 2014

Related party expense

The Company has related party expense as described in the following table (in thousands):



	December 31,
	2014		2013		2012
Office space lease (a)	$	—	$	70	$	48
Aircraft use (b)	10		11		—
Furniture (c)	41		—		—
Line of credit (d)	—		—		104
Convertible senior secured promissory notes (e)	—		—		50
	$	51	$	81	$	202


(a)	payments related to the lease of office space from an entity owned by the Chairman of the Board and CEO


(b)	payments related to aircraft use from an entity owned by the Chairman of the Board and CEO


(c)	payment to Chairman of the Board and CEO for office furniture purchased for Company headquarters


(d)	interest related to a revolving secured line of credit extended by the Chairman of the Board and CEO dated March 31, 2011


(e)	interest related to the convertible senior secured promissory notes issued to the Chairman of the Board and CEO during the fourth quarter of 2011

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Estimated annual lease, royalty, and employment agreement expenses

The estimated annual payments are as follows (in thousands):



Year ended December 31,
2015	$	2,094
2016	1,924
2017	1,535
2018	1,434
2019	120
	$	7,107

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information



		First Quarter			Second Quarter			Third Quarter			Fourth Quarter
NET SALES	2014	$	19,559		$	25,573		$	33,518		$	39,573
	2013	11,556			13,515			16,116			17,994
	2012	3,706			4,884			7,954			10,509

GROSS MARGIN	2014	$	16,582		$	22,833		$	30,170		$	35,973
	2013	9,651			11,316			14,002			14,883
	2012	2,747			3,769			6,529			8,820

NET INCOME	2014	$	(922	)	$	(390	)	$	3,700		$	3,832
	2013	(1,620		)	(757		)	(307		)	(1,427		)
	2012	(1,094		)	(744		)	(4,219		)	(1,605		)

NET INCOME (LOSS) PER COMMON SHARE - BASIC	2014	$	(0.01	)	$	—		$	0.03		$	0.04
	2013	(0.02		)	(0.01		)	—			(0.01		)
	2012	(0.01		)	(0.01		)	(0.05		)	(0.01		)

NET INCOME (LOSS) PER COMMON SHARE - DILUTED	2014	$	(0.01	)	$	—		$	0.03		$	0.03
	2013	(0.02		)	(0.01		)	—			(0.01		)
	2012	(0.01		)	(0.01		)	(0.05		)	(0.01		)

Nature of Business (Details)	12 Months Ended
Nature of Business (Details)	Dec. 31, 2014 Business_Segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments	1

Significant Accounting Policies (Details)	3 Months Ended	12 Months Ended
Significant Accounting Policies (Details)	Dec. 31, 2013 USD ($)	Dec. 31, 2014 USD ($) distributor	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Jul. 31, 2010 USD ($)
Market Concentrations and Credit Risk [Line Items]
FDIC insured amount					$ 250,000
Cash and cash equivalents uninsured amount		$ 44,600,000
Number of major customers \| distributor		1
Impairment of intangible assets			$ 368,000	$ 1,800,000
Impairment of Long-lived Assets [Abstract]
Impairment loss	$ 30,000
Grant Income [Abstract]
Proceeds from grant			250,000
Patents
Impairment of Long-lived Assets [Abstract]
Intangible assets, net of accumulated amortization		$ 594,000	$ 689,000	$ 0
Minimum
Property and Equipment [Abstract]
Property and equipment estimated useful life		3 years
Maximum
Property and Equipment [Abstract]
Property and equipment estimated useful life		7 years
Revenue \| AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk		34.00%	56.00%	40.00%
Accounts Receivable \| AvKare
Market Concentrations and Credit Risk [Line Items]
Concentration of risk		33.00%	55.00%	53.00%

Liquidity and Capital Resources (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Liquidity and Capital Resources [Abstract]
Cash and cash equivalents	$ 46,582	$ 44,078	$ 6,754	$ 4,113
Total current assets	85,677	65,389
Total current liabilities	18,404	9,608
Net working capital	67,300
Net cash flows from operating activities	$ 16,802	$ (284)	$ (3,332)

Cash Equivalents and Short Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 46,582	$ 44,078	$ 6,754	$ 4,113
Short term investments	5,750	$ 0
Certificates of Deposit
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	1,250
Short term investments	$ 5,750

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]
Raw materials	$ 255	$ 202
Work in process	3,419	2,952
Finished goods	1,986	1,049
Inventory, gross	5,660	4,203
Reserve for obsolescence	(527)	(322)
Inventory, net	$ 5,133	$ 3,881

Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013
Investment [Line Items]
Investments	$ 3,250	$ 0
Certificates of Deposit
Investment [Line Items]
Investments	$ 3,250

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property and equipment [Line Items]
Property and equipment, gross	$ 8,946	$ 6,388
Less accumulated depreciation	(3,499)	(2,302)
Property and equipment, net	5,447	4,086
Depreciation expense	1,197	637	$ 465
Leasehold improvements
Property and equipment [Line Items]
Property and equipment, gross	2,559	2,320
Lab and clean room equipment
Property and equipment [Line Items]
Property and equipment, gross	3,040	2,025
Furniture and equipment
Property and equipment [Line Items]
Property and equipment, gross	2,398	1,241
Construction in Progress
Property and equipment [Line Items]
Property and equipment, gross	949	$ 802
Capital Leases
Property and equipment [Line Items]
Property and equipment, net	250
Leasehold improvements paid for by landlord
Property and equipment [Line Items]
Property and equipment, net	$ 1,000

Intangible Assets and Royalty Agreement (Details) - USD ($)
$ in Thousands

12 Months Ended

Jan. 29, 2007

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Jan. 05, 2011

Finite-Lived Intangible Assets [Line Items]

Intangible Assets, Gross Carrying Value

$ 14,776

$ 14,182

Less Accumulated amortization

(3,931)

(3,003)

Intangible Assets, Net

10,845

11,179

Net book value

9,837

Amortization of intangible assets

928

1,054

$ 1,380

Estimated future amortization expense [Abstract]

929

929

840

830

830

5,479

9,837

Tradenames & Trademarks

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

1,008

Tradenames & Trademarks | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

$ 1,008

In Process Research & Development

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

In Process Research & Development | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

Patents in Process

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value, Indefinite Lived

$ 1,082

580

Licenses

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

^[1],[2],[3]

10 years

Gross Carrying Value

^[1],[2],[3]

$ 1,009

1,009

Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.

Finite-Lived Intangible Assets [Line Items]

Acquisition price

$ 996

Maximum time of approval

30 days

Contingent payments to licensor

$ 200

Contingent royalty to be paid to licensor

3.00%

Annual royalty payment

$ 50

Net book value

$ 209

Estimated future amortization expense [Abstract]

Net book value

$ 209

Licenses | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

^[1],[2],[3]

Patents & Know How

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

17 years

Gross Carrying Value

$ 7,891

7,799

Patents & Know How | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

7,690

Finite-Lived Intangible Assets, Costs

$ 92

Customer & Supplier Relationships

Finite-Lived Intangible Assets [Line Items]

Weighted Average Amortization Lives

14 years

Gross Carrying Value

$ 3,761

Customer & Supplier Relationships | Surgical Biologics, LLC

Finite-Lived Intangible Assets [Line Items]

Gross Carrying Value

$ 3,761

[1]	Capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
[2]	On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of December 31, 2014, this license had a remaining net book value of approximately $209,000.
[3]	On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. During 2014 approximately $92,000 of additional costs associated with patents granted during the year were capitalized and included in Patents & Know- How subject to amortization.

Long-Term Debt (Details) - USD ($)		2 Months Ended	12 Months Ended
Long-Term Debt (Details) - USD ($)	Dec. 31, 2011	Feb. 28, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	May 01, 2014
Debt Instrument [Line Items]
Placement fee, warrants issued (in shares)			15,958
5% Convertible Senior Secured Promissory Note
Debt Instrument [Line Items]
Warrant exercise price (in dollars per share)	$ 1.09
Annual interest rate	5.00%			5.00%
Proceeds from issuance of debt	$ 5,000,000
Principal of notes convertible (in shares)	5,000,000
Accrued but unpaid interest (in dollars per share)	$ 1.00
Placement fee	$ 32,800
Placement fee, warrants issued (in shares)	42,400
Fair value of placement fee warrants	$ 15,000
Direct costs of sale of notes	47,800
5% Convertible Senior Secured Promissory Note \| Chairman and CEO
Debt Instrument [Line Items]
Proceeds from issuance of debt	$ 500,000
Loan Agreement
Debt Instrument [Line Items]
Total amount of debt plus accrued interest		$ 5,272,000
Convertible secured promissory note to common stock (in shares)		5,272,000
Amortization of debt discount				$ 1,328,000	$ 1,714,000
Loan Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 3,000,000
Borrowings outstanding			$ 0
Loan Agreement \| Chief Executive Officer
Debt Instrument [Line Items]
Convertible secured promissory note to common stock (in shares)		532,260

Net Income (loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Earnings Per Share [Abstract]
Net income (loss)	$ 3,832	$ 3,700	$ (390)	$ (922)	$ (1,427)	$ (307)	$ (757)	$ (1,620)	$ (1,605)	$ (4,219)	$ (744)	$ (1,094)	$ 6,220	$ (4,112)	$ (7,663)
Denominator for basic earnings per share - weighted average shares													105,793,008	96,285,504	81,646,295
Effect of dilutive securities: Stock options and warrants outstanding and convertible debt (in shares)													7,502,496	0	0
Denominator for diluted earnings per share - weighted average shares adjusted for dilutive securities													113,295,504	96,285,504	81,646,295
Income (loss) per common share - basic (in dollars per share)	$ 0.04	$ 0.03	$ 0.00	$ (0.01)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.01)	$ (0.01)	$ 0.06	$ (0.04)	$ (0.09)
Income (loss) per common share - diluted (in dollars per share)	$ 0.03	$ 0.03	$ 0.00	$ (0.01)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.01)	$ (0.01)	$ 0.05	$ (0.04)	$ (0.09)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													7,502,496
Outstanding Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													7,036,088
Outstanding Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													226,926
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)													239,482

Common Stock Placements (Details) - Common Stock $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2013 USD ($) $ / shares shares	Dec. 31, 2013 $ / shares shares
Sale of stocks and warrants [Line Items]
Shares issued (in shares) \| shares	5,750,000	5,750,000
Share issue price (in dollars per share) \| $ / shares	$ 6.80	$ 6.80
Proceeds from shares issued	$ 36,704
Legal fees paid for secondary offering	$ 194

Equity (Narrative) (Details)		2 Months Ended	8 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
Equity (Narrative) (Details)	Jan. 06, 2015 USD ($)	Mar. 13, 2015 USD ($)	Dec. 31, 2014 USD ($) shares	Sep. 30, 2014 shares	Mar. 13, 2015 USD ($)	Dec. 31, 2014 USD ($) plan $ / shares shares	Dec. 31, 2013 USD ($) $ / shares	Dec. 31, 2012 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share-based compensation plans \| plan						3
Outstanding assumed options (in shares) \| shares			195,000			195,000
Additional shares authorized by Board of Directors (in shares) \| shares				4,000,000
Number of shares available to be issued (in shares) \| shares				26,500,000
Intrinsic value of options exercised						$ 10,566,000	$ 8,864,000	$ 719,000
Intrinsic value of options vested						6,615,000	$ 3,351,000	$ 1,851,000
Total unrecognized compensation expense			$ 15,084,000			$ 15,084,000
Weighted-average grant date fair value for options granted during the period (in dollars per share) \| $ / shares						$ 4.18	$ 3.08	$ 1.07
Authorized share amount for repurchase			$ 10,000,000
Stock repurchase (in shares) \| shares						940,000
Shares repurchased, value						$ 5,612,000
Remaining authorizations under the repurchase program						$ 4,400,000
Subsequent Event
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized share amount for repurchase	$ 20,000,000
Shares repurchased, value		$ 12,300,000			$ 17,800,000

Equity (Activity of Stock Options) (Details)

12 Months Ended

Dec. 31, 2014

USD ($)

$ / shares

Number of Shares

Outstanding, beginning of period (in shares) | shares

15,375,960

Granted (in shares) | shares

3,132,969

Exercised (in shares) | shares

(1,653,690)

Unvested options forfeited (in shares) | shares

(296,680)

Vested options expired (in shares) | shares

(84,332)

Outstanding, end of period (in shares) | shares

16,474,227

Vested at end of period (in shares) | shares

9,280,650

Exercisable options, vested and expected to vest (in shares) | shares

16,198,892

^[1]

Weighted- Average Exercise Price

Outstanding, weighted average exercise price, beginning of period (in dollars per share) | $ / shares

$ 2.46

Granted, weighted average exercise price (in dollars per share) | $ / shares

7.20

Exercised, weighted average exercise price (in dollars per share) | $ / shares

1.49

Unvested options forfeited weighted-average exercise price (in dollars per share) | $ / shares

4.09

Vested options expired weighted-average exercise price (in dollars per share) | $ / shares

0.81

Outstanding, weighted average exercise price, end of period (in dollars per share) | $ / shares

3.43

Vested at end of period weighted average exercise price (in dollars per share) | $ / shares

1.97

Vested and expected to vest, weighted average exercise price (in dollars per share) | $ / shares

$ 3.38

^[1]

Stock options, additional disclosures

Outstanding Options, weighted average remaining contractual term

7 years 3 months 18 days

Vested at end of period weighted average remaining contractual term

6 years 6 months

Vested and expected to vest, weighted average remaining contractual term

7 years 3 months 18 days

^[1]

Outstanding intrinsic value | $

$ 133,360,210

Vested at end of period aggregate intrinsic value | $

88,716,569

Vested and expected to vest, aggregate intrinsic value | $

$ 131,953,654

^[1]

[1]	Includes forfeiture adjusted unvested shares.

Equity (Exercise Price Ranges) (Details)	12 Months Ended
Equity (Exercise Price Ranges) (Details)	Dec. 31, 2014 $ / shares shares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options (in shares) \| shares	16,474,227
Outstanding Options, weighted average remaining contractual term	7 years 3 months 18 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 3.43
Number of exercisable options (in shares) \| shares	9,280,650
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.97
$0.50 - $0.76
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	0.50
Exercise Price Range, upper range limit (in dollars per share)	$ 0.76
Number of outstanding options (in shares) \| shares	632,500
Outstanding Options, weighted average remaining contractual term	4 years 4 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 0.72
Number of exercisable options (in shares) \| shares	632,500
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0.72
$0.87 - $1.35
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	0.87
Exercise Price Range, upper range limit (in dollars per share)	$ 1.35
Number of outstanding options (in shares) \| shares	5,861,595
Outstanding Options, weighted average remaining contractual term	6 years 7 months 6 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 1.20
Number of exercisable options (in shares) \| shares	4,989,245
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.19
$1.40 - $2.29
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	1.40
Exercise Price Range, upper range limit (in dollars per share)	$ 2.29
Number of outstanding options (in shares) \| shares	1,460,201
Outstanding Options, weighted average remaining contractual term	5 years
Outstanding Options, weighted average exercise price (in dollars per share)	$ 1.64
Number of exercisable options (in shares) \| shares	1,338,532
Exercisable Options, weighted average exercise price (in dollars per share)	$ 1.65
$2.33 - $3.75
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	2.33
Exercise Price Range, upper range limit (in dollars per share)	$ 3.75
Number of outstanding options (in shares) \| shares	1,737,339
Outstanding Options, weighted average remaining contractual term	7 years 8 months 12 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 2.77
Number of exercisable options (in shares) \| shares	1,079,147
Exercisable Options, weighted average exercise price (in dollars per share)	$ 2.78
$3.95 - $5.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	3.95
Exercise Price Range, upper range limit (in dollars per share)	$ 5.99
Number of outstanding options (in shares) \| shares	3,365,030
Outstanding Options, weighted average remaining contractual term	8 years 4 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 5.15
Number of exercisable options (in shares) \| shares	977,415
Exercisable Options, weighted average exercise price (in dollars per share)	$ 5.10
$6.02- $9.13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	6.02
Exercise Price Range, upper range limit (in dollars per share)	$ 9.13
Number of outstanding options (in shares) \| shares	3,287,562
Outstanding Options, weighted average remaining contractual term	8 years 9 months 18 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 7.06
Number of exercisable options (in shares) \| shares	263,811
Exercisable Options, weighted average exercise price (in dollars per share)	$ 6.47
$9.22 - $10.99
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price Range, lower range limit (in dollars per share)	9.22
Exercise Price Range, upper range limit (in dollars per share)	$ 10.99
Number of outstanding options (in shares) \| shares	130,000
Outstanding Options, weighted average remaining contractual term	9 years 10 months 24 days
Outstanding Options, weighted average exercise price (in dollars per share)	$ 10.42
Number of exercisable options (in shares) \| shares	0
Exercisable Options, weighted average exercise price (in dollars per share)	$ 0.00

Equity (Summary of Unvested Stock Options) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Shares
Unvested at (in shares)	8,568,228
Granted (in shares)	3,132,969
Called/expired (in shares)	(296,680)
Vested (in shares)	(4,210,940)
Unvested at (in shares)	7,193,577	8,568,228
Weighted- Average Grant Date Fair Value
Unvested at (in dollars per share)	$ 1.94
Granted (in dollars per share)	4.18	$ 3.08	$ 1.07
Cancelled/expired (in dollars per share)	4.09
Vested (in dollars per share)	1.58
Unvested at (in dollars per share)	$ 3.08	$ 1.94

Equity (Assumptions) (Details)	12 Months Ended
Equity (Assumptions) (Details)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair value options valuation assumptions [Abstract]
Expected life (in years)	6 years	6 years	6 years
Expected dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate, minimum	1.64%	0.85%	0.62%
Risk-free interest rate, maximum	1.96%	1.88%	1.77%
Minimum
Fair value options valuation assumptions [Abstract]
Expected volatility	58.14%	61.41%	45.70%
Maximum
Fair value options valuation assumptions [Abstract]
Expected volatility	64.50%	64.77%	64.30%

Equity (Summary of Restricted Stock Awards) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for services performed (in shares)	15,958
Stock issuance of 15,958 shares in exchange for services performed	$ 117,000	$ 0	$ 0
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for services performed (in shares)	15,958
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized stock-based compensation related to time-based, nonvested restricted stock	$ 6,637,000
Expenses expected to be recognized over a weighted-average period	2 years 2 months 12 days
Number of Shares
Unvested at	576,550
Granted	862,739
Forfeited	(720)
Vested	(209,671)
Unvested at	1,228,898	576,550
Weighted- Average Grant Date Fair Value
Unvested at (in dollars per share)	$ 5.53
Granted (in dollars per share)	7.88
Forfeited (in dollars per share)	7.24
Vested (in dollars per share)	5.71
Unvested at (in dollars per share)	$ 5.53	$ 5.53
Minimum \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Maximum \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Consultant \| Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for services performed (in shares)	8,411
Stock issuance of 15,958 shares in exchange for services performed	$ 70,000

Equity (Recognized Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation [Abstract]
Stock-based compensation expense	$ 11,453	$ 6,010	$ 2,539
Cost of sales
Share-based Compensation [Abstract]
Stock-based compensation expense	322	279	98
Research and development
Share-based Compensation [Abstract]
Stock-based compensation expense	660	417	289
Selling, general and administrative
Share-based Compensation [Abstract]
Stock-based compensation expense	$ 10,471	$ 5,314	$ 2,152

Equity (Warrants) (Details)	12 Months Ended
Equity (Warrants) (Details)	Dec. 31, 2014 $ / Right shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, term	5 years
Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants outstanding, beginning of period (in shares) \| shares	1,284,816
Warrants outstanding, end of period (in shares) \| shares	42,400
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants outstanding, beginning of period (in dollars per share) \| $ / Right	0.90
Warrants outstanding, end of period (in dollars per share) \| $ / Right	1.09
Other \| Warrants
Warrants, Number of Warrants [Roll Forward]
Warrants exercised (in shares) \| shares	(1,242,416)
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]
Warrants exercised (in dollars per share) \| $ / Right	0.90

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets and liabilities [Abstract]
Accruals and prepaids	$ 3,563,000	$ 1,404,000
Intangible assets	619,000	1,163,000
Property and equipment	(770,000)	(507,000)
R&D and other tax credits	2,086,000	1,369,000
Stock compensation	4,163,000	2,151,000
Charitable contributions	1,000	1,000
Federal and state basis difference	114,000	0
Net operating loss	6,382,000	14,663,000
Net deferred tax assets	16,158,000	20,244,000
Valuation allowance	(16,158,000)	(20,244,000)
Deferred tax assets and liabilities, net of valuation allowance	$ 0	$ 0
Reconciliation of the Federal statutory income tax rate [Abstract]
Federal statutory rate	34.00%	34.00%
State taxes, net of federal benefit	9.58%	(2.48%)
Non deductible compensation	5.59%	0.00%
Meals & entertainment	5.55%	0.00%
Stock based compensation - ISO	21.73%	0.00%
Other	(5.92%)	12.73%
Valuation allowance	(58.73%)	(46.73%)
Effective income tax rate	11.80%	(2.48%)
Operating Loss Carryforwards [Line Items]
Net deferred tax assets	$ 16,158,000	$ 20,244,000
Stock compensation	5,676,000
Federal
Deferred tax assets and liabilities [Abstract]
Net deferred tax assets	5,210,000
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	15,323,000
Net deferred tax assets	5,210,000
State
Deferred tax assets and liabilities [Abstract]
Net deferred tax assets	1,172,000
Operating Loss Carryforwards [Line Items]
Operating loss carry forwards	21,196,000
Net deferred tax assets	$ 1,172,000

Supplemental Disclosure of Cash Flow and Non-Cash Investing and Financing Activities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash and Cash Equivalents [Line Items]
Cash paid for interest	$ 48	$ 36	$ 13
Income taxes paid	384	61	0
Purchases of equipment financed through capital leases	0	355	85
Stock issuance of 167,086 shares in lieu of Directors' fees	0	$ 0	184
Stock issuance in lieu of Directors' fees (in shares)		167,086
Deferred financing costs	0	$ 27	20
Beneficial conversion related to related party	0	0	514
Stock issuance in connection with Earn-Out Liability of 1,174,915 shares for 2013 and 2,632,576 shares for 2012	$ 0	$ 5,792	3,186
Stock issued for earn-out liability (in shares)	1,174,915	2,632,576
Stock issuance in exchange for convertible debt of 5,272,004 shares	$ 0	$ 5,272	0
Stock issued for convertible debt (in shares)	5,272,004
Stock issuance of 1,403,630 shares for payment of Line of Credit with related party	$ 0	$ 0	1,403
Stock issued during period, shares, issued for payment of Line of Credit with related party (shares)		1,403,630
Stock issuance of 15,958 shares in exchange for services performed	$ 117	$ 0	0
Shares issued for services performed (in shares)	15,958
Stock issuance of 216,085 shares for exercise of cashless warrants	$ 0	$ 0	216
Shares issued for Cashless Exercise (in shares)		216,085
Stock issuance of 893,267 shares in payment of Convertible Secured Promissory Notes related to acquisition of Surgical Biologics	$ 0	$ 0	$ 893
Stock issued related to acquisition of Surgical Biologics (in shares)	893,267	893,267	893,267
Tenant improvement incentive	$ 0	$ 997	$ 0
Legal fees paid for public offering	0	102	0
Accounts payable
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	0	30	0
Accrued expenses
Cash and Cash Equivalents [Line Items]
Legal fees paid for public offering	$ 0	$ 62	$ 0

Related Party Transactions (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Related party expense

$ 51

$ 81

$ 202

Line of credit

Interest expense

^[1]

104

Convertible senior secured promissory notes

Interest expense

^[2]

Office space lease

Related party expense

^[3]

Aircraft use

Related party expense

^[4]

Furniture

Related party expense

^[5]

$ 41

$ 0

[1]	interest related to a revolving secured line of credit extended by the Chairman of the Board and CEO dated March 31, 2011
[2]	interest related to the convertible senior secured promissory notes issued to the Chairman of the Board and CEO during the fourth quarter of 2011
[3]	payments related to the lease of office space from an entity owned by the Chairman of the Board and CEO
[4]	payments related to aircraft use from an entity owned by the Chairman of the Board and CEO
[5]	payment to Chairman of the Board and CEO for office furniture purchased for Company headquarters

401k Plan (Details)	12 Months Ended
401k Plan (Details)	Dec. 31, 2014 USD ($)
Compensation and Retirement Disclosure [Abstract]
Minimum age require to qualify for pension plan	21 years
Minimum service period require to qualify for pension plan	3 months
Maximum wages deferred	100.00%
Maximum eligible wages deferred by participants per year	$ 17,500
Minimum age for additional contribution beyond normal plan	50 years
Defined benefit plan, contributions by plan participants	$ 5,500
Employer matching contribution	6.00%

Commitments and Contingencies (Details) $ in Thousands	12 Months Ended
Commitments and Contingencies (Details) $ in Thousands	Dec. 31, 2014 USD ($) clinical_site patient	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
2015	$ 2,094
2016	1,924
2017	1,535
2018	1,434
2019	120
Total Contractual commitments	7,107
Rent and operating leases expense	$ 1,130	$ 1,000	$ 485
Number of patients \| patient	150
Letters of Credit
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
Standby letters of credit	$ 500
Minimum
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
Number of clinical sites \| clinical_site	10
Maximum
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
Number of clinical sites \| clinical_site	20
Product Concentration Risk \| Sales Revenue, Net
Estimated annual lease, royalty, and employment agreement expenses [Abstract]
Percentage of revenue	14.00%

Quarterly Financial Data (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
NET SALES	$ 39,573	$ 33,518	$ 25,573	$ 19,559	$ 17,994	$ 16,116	$ 13,515	$ 11,556	$ 10,509	$ 7,954	$ 4,884	$ 3,706	$ 118,223	$ 59,181	$ 27,053
GROSS MARGIN	35,973	30,170	22,833	16,582	14,883	14,002	11,316	9,651	8,820	6,529	3,769	2,747	105,558	49,853	21,865
Net income (loss)	$ 3,832	$ 3,700	$ (390)	$ (922)	$ (1,427)	$ (307)	$ (757)	$ (1,620)	$ (1,605)	$ (4,219)	$ (744)	$ (1,094)	$ 6,220	$ (4,112)	$ (7,663)
Net income (loss) per common share - basic (in dollars per share)	$ 0.04	$ 0.03	$ 0.00	$ (0.01)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.01)	$ (0.01)	$ 0.06	$ (0.04)	$ (0.09)
Net income (loss) per common share - diluted (in dollars per share)	$ 0.03	$ 0.03	$ 0.00	$ (0.01)	$ (0.01)	$ 0.00	$ (0.01)	$ (0.02)	$ (0.01)	$ (0.05)	$ (0.01)	$ (0.01)	$ 0.05	$ (0.04)	$ (0.09)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Subsequent Events (Details) ft² in Thousands, member in Millions, life in Millions				2 Months Ended	8 Months Ended	10 Months Ended	12 Months Ended
	Mar. 05, 2015 life member	Feb. 24, 2015 USD ($) ft²	Jan. 06, 2015 USD ($)	Mar. 13, 2015 USD ($)	Dec. 31, 2014 USD ($)	Mar. 13, 2015 USD ($)	Dec. 31, 2014 USD ($)
Subsequent Event [Line Items]
Authorized share amount for repurchase					$ 10,000,000
Shares repurchased, value							$ 5,612,000
Subsequent Event
Subsequent Event [Line Items]
Authorized share amount for repurchase			$ 20,000,000
Shares repurchased, value				$ 12,300,000		$ 17,800,000
Area of property leased \| ft²		26
Term of lease		63 months
Base rental payments		$ 1,600,000
Anthem \| Subsequent Event
Subsequent Event [Line Items]
Number of members \| member	34
Number of covered lives \| life	149
Percent of covered lives	60.00%

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	$ 407	$ 49	$ 19
Additions charged to Expense or Revenue	1,357	391	57
Deductions and write-offs	(14)	(33)	(27)
Balance at End of Year	1,750	407	49
Allowance for product returns
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	215	89	88
Additions charged to Expense or Revenue	2,215	917	394
Deductions and write-offs	(1,589)	(791)	(393)
Balance at End of Year	841	215	89
Allowance for obsolescence
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Year	322	159	53
Additions charged to Expense or Revenue	405	213	106
Deductions and write-offs	(200)	(50)	0
Balance at End of Year	$ 527	$ 322	$ 159